Table 3.

Safety summary and treatment-related AEs

All patients with LGG (N = 32)
All gradeGrade 3/4
Patients with a treatment-related AE, n (%)29 (91)9 (28)
 Treatment-related AEs (in >20% of patients), n (%)
  Fatigue11 (34)0
  Rash10 (31)0
  Dry skin9 (28)0
  Pyrexia9 (28)0
  Rash maculopapular9 (28)3 (9)
  Arthralgia8 (25)1 (3)
  Headache7 (22)0
  Vomiting7 (22)0
AEs leading to discontinuation, n (%)2 (6)2 (6)
Treatment-related deaths, n (%)00
Patients with a treatment-related serious AE, n (%)5 (16)3 (9)
 Treatment-related serious AEs, n (%)
  Arthralgia1 (3)1 (3)
  Disseminated intravascular coagulation1 (3)1 (3)
  Ejection fraction decreased1 (3)0
  Febrile neutropenia1 (3)0
  Hypotension1 (3)1 (3)
  Pyrexia1 (3)0
  Rash maculopapular1 (3)1 (3)